TONIX Pharmaceuticals Holding Corp.

Company Listings from SPi: TONIX Pharmaceuticals Holding Corp.

You are here: Home >> SPi Company Listings >> TONIX Pharmaceuticals Holding Corp.

 

TONIX Pharmaceuticals Holding Corp.

Website:
http://

Search for other references to "tonix" on SPi News

Latest TONIX Pharmaceuticals Holding Corp. News

Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL NEW YORK, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix), a clinical-stage biopharmaceutical company, today announced that it has co...... 12:00 GMT Friday 24th January 2020

Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced...... 12:00 GMT Thursday 23rd January 2020

Tonix Pharmaceuticals to Present at Biotech Showcase 2020 NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chie...... 12:00 GMT Tuesday 7th January 2020

Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced...... 20:15 GMT Monday 16th December 2019

Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced...... 21:05 GMT Wednesday 11th December 2019

Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced...... 12:00 GMT Tuesday 10th December 2019

Tonix Pharmaceuticals to Present at 12th Annual LD Micro Main Event NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at the...... 12:00 GMT Wednesday 4th December 2019

Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, today announced...... 12:00 GMT Tuesday 3rd December 2019

Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced...... 21:05 GMT Tuesday 26th November 2019

Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chie...... 21:05 GMT Monday 25th November 2019

Buy TONIX Pharmaceuticals Holding Corp.
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2020. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us